Eli Lilly Offers Expanded Access to New Obesity Medication

In a significant move for patients struggling with severe, treatment-resistant obesity, Eli Lilly has launched an 'expanded access' program for its experimental drug, retatrutide.

While the medication awaits official FDA approval—expected in early 2027—this new program offers a path for eligible individuals to receive treatment before it reaches the general market.

Retatrutide is notable for being a 'triple agonist,' meaning it targets three different hormone receptors to manage metabolism, potentially offering higher efficacy than current double-agonist treatments.

Eligibility is strict, requiring patients to be at least 18 years old, to have failed other obesity therapies, and to have two or more serious health complications.

Crucially, access is not requested by patients directly, but must be initiated by a physician and approved by the FDA and an institutional review board.

Meanwhile, Eli Lilly continues its broader strategy to improve obesity care, including Medicare price caps for its drug Zepbound and the ongoing use of its LillyDirect platform to help patients navigate access to medication.

This development marks a proactive step in addressing the urgent needs of the medical community.